Association between human papillomavirus andEGFRmutations in advanced lung adenocarcinoma.
Previous studies have demonstrated an association between human papillomavirus (HPV) and mutations in the epidermal growth factor receptor (EGFR) gene in lung cancer patients; however, few studies have investigated this association in advanced lung adenocarcinoma patients undergoing gefitinib treatment. The present study investigated the association between HPV andEGFRmutations in advanced lung adenocarcinoma patients. A total of 95 advanced lung adenocarcinoma patients were enrolled in the study. The HPV infection status and presence ofEGFRmutations in tumor tissue was evaluated. Patient clinical characteristics were also determined and compared with HPV infection andEGFRmutation status to analyze their impact on progression-free survival. HPV DNA was identified in 27/95 (28.4%) lung adenocarcinoma tumors and was most common in patients with lymph node metastasis (P=0.016). A total of 44/95 (46.3%) cases exhibitedEGFRmutations, which were predominantly observed in female patients and non-smokers. The presence of HPV DNA was significantly associated withEGFRmutations (P=0.012) and multivariate analysis also revealed that HPV DNA was significantly associated withEGFRmutations (odds ratio=3.971) in advanced lung adenocarcinoma. Patients with both HPV infections andEGFRmutations exhibit a marked decrease in the risk of lung cancer progression when compared with those without HPV infection orEGFRmutations (adjusted HR=0.640; 95% confidence interval: 0.488-0.840; P=0.001). HPV infection was significantly associated withEGFRmutations in advanced lung adenocarcinoma patients. Furthermore, patients with HPV infections exhibited the longest progression-free survival times, which may be due to good response to tyrosine kinase inhibitor- or platinum-based-adjuvant therapy in these patients. Patients withEGFRmutations exhibited a better prognosis when compared with those exhibiting wild-typeEGFR, regardless of HPV status.
Department of Clinical Laboratory, Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui 230001, P.R. China; Department of Clinical Laboratory, Anhui Provincial Cancer Hospital, Hefei, Anhui 230031, P.R. China.
Ming
M
Li
Department of Clinical Laboratory, Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui 230001, P.R. China; Department of Clinical Laboratory, Anhui Provincial Cancer Hospital, Hefei, Anhui 230031, P.R. China.
Fang
F
Deng
Department of Clinical Laboratory, Anhui Provincial Cancer Hospital, Hefei, Anhui 230031, P.R. China.
Li-Ting
LT
Qian
Department of Respiratory Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui 230031, P.R. China.
Shui-Ping
SP
Meng
Department of Clinical Laboratory, Anhui Provincial Cancer Hospital, Hefei, Anhui 230031, P.R. China.
Yang
Y
Zhang
Department of Clinical Laboratory, Anhui Provincial Cancer Hospital, Hefei, Anhui 230031, P.R. China.
Wu-Lin
WL
Shan
Department of Clinical Laboratory, Anhui Provincial Cancer Hospital, Hefei, Anhui 230031, P.R. China.
Xiao-Lei
XL
Zhang
Department of Clinical Laboratory, Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui 230001, P.R. China.
Bao-Long
BL
Wang
epidermal growth factor receptor; human papillomavirus; lung adenocarcinoma; mutation; survival